The Experts below are selected from a list of 2931 Experts worldwide ranked by ideXlab platform

Daniel Romo - One of the best experts on this subject based on the ideXlab platform.

Henry Nguyen - One of the best experts on this subject based on the ideXlab platform.

Zhengchun Peng - One of the best experts on this subject based on the ideXlab platform.

  • pH-Responsive Dual Drug-Loaded Nanocarriers Based on Poly (2-Ethyl-2-Oxazoline) Modified Black Phosphorus Nanosheets for Cancer Chemo/Photothermal Therapy
    'Frontiers Media SA', 2019
    Co-Authors: Nansha Gao, Chenyang Xing, Haifei Wang, Liwen Feng, Xiaowei Zeng, Lin Mei, Zhengchun Peng
    Abstract:

    Synergistic cancer therapy, such as those combining chemotherapeutic and photothermal methods, has stronger treatment effect than that of individual ones. However, it is challenging to efficiently deliver nanocarriers into tumor cells to elevate intracellular drug concentration. Herein, we developed an effective pH-responsive and dual drug co-delivery platform for combined chemo/photothermal therapy. An anticancer drug doxorubicin (DOX) was first loaded onto the surface of black phosphorus (BP). With poly(2-ethyl-2-oxazoline) (PEOz) ligand conjugated onto the polydopamine (PDA) coated BP nanosheets, targeted long circulation and cellular uptake in vivo was significantly improved. With another anticancer drug bortezomib (BTZ) loaded onto the surface of the nanocapsule, the platform can co-deliver two different drugs. The surface charge of the nanocapsule was reversed from negative to positive at the tumor extracellular pH (∼6.8), ionizing the Tertiary Amide groups along the PEOz chain, thus facilitating the cell internalization of the nanocarrier. The cytotoxicity therapeutic effect of this nanoplatform was further augmented under near-infrared laser irradiation. As such, our DOX-loaded BP@PDA-PEOz-BTZ platform is very promising to synergistic cancer therapy

  • Data_Sheet_1_pH-Responsive Dual Drug-Loaded Nanocarriers Based on Poly (2-Ethyl-2-Oxazoline) Modified Black Phosphorus Nanosheets for Cancer Chemo/Photothermal Therapy.docx
    2019
    Co-Authors: Nansha Gao, Chenyang Xing, Haifei Wang, Liwen Feng, Xiaowei Zeng, Lin Mei, Zhengchun Peng
    Abstract:

    Synergistic cancer therapy, such as those combining chemotherapeutic and photothermal methods, has stronger treatment effect than that of individual ones. However, it is challenging to efficiently deliver nanocarriers into tumor cells to elevate intracellular drug concentration. Herein, we developed an effective pH-responsive and dual drug co-delivery platform for combined chemo/photothermal therapy. An anticancer drug doxorubicin (DOX) was first loaded onto the surface of black phosphorus (BP). With poly(2-ethyl-2-oxazoline) (PEOz) ligand conjugated onto the polydopamine (PDA) coated BP nanosheets, targeted long circulation and cellular uptake in vivo was significantly improved. With another anticancer drug bortezomib (BTZ) loaded onto the surface of the nanocapsule, the platform can co-deliver two different drugs. The surface charge of the nanocapsule was reversed from negative to positive at the tumor extracellular pH (∼6.8), ionizing the Tertiary Amide groups along the PEOz chain, thus facilitating the cell internalization of the nanocarrier. The cytotoxicity therapeutic effect of this nanoplatform was further augmented under near-infrared laser irradiation. As such, our DOX-loaded BP@PDA-PEOz-BTZ platform is very promising to synergistic cancer therapy.

James F Wolfe - One of the best experts on this subject based on the ideXlab platform.

  • synthesis of succinimido 3 4 b indane and 1 2 3 4 5 6 hexahydro 1 5 methano 3 benzazocine 2 4 dione by sequential alkylation and intramolecular arylation of enolates derived from n n n n tetramethylbutanediAmides and n n n n tetramethylpentanediAmide
    Journal of Organic Chemistry, 1999
    Co-Authors: Sushama A Dandekar, Stacey N Greenwood, Thomas D Greenwood, Stephane Mabic, Joseph S Merola, James M Tanko, James F Wolfe
    Abstract:

    The tricyclic title compounds, 4 and 5, were synthesized by initial alkylation of the lithium monoenolates of N,N,N‘,N‘-tetramethylbutanediAmide (6) and N,N,N‘,N‘-tetramethylpentanediAmide (19) with 2-iodobenzyl chloride in liquid NH3 at −60 °C to afford 2-(2-iodobenzyl)-N,N,N‘,N‘-tetramethylbutanediAmide (9) and 2-(2-iodobenzyl)-N,N,N‘,N‘-tetramethylpentanediAmide (20) in yields of 88 and 87%, respectively. Treatment of 9 with KNH2 in liquid NH3 resulted in formation and intramolecular arylation of the less-substituted α-enolate to produce trans-1,2-bis(N,N-dimethylcarboxamido)indane (10a) in 60% yield. Selective hydrolysis of 10a with aqueous Na2O2 gave trans-1-(N,N-dimethylcarboxamido)indane-2-carboxylic acid (17), which was then converted to bridged succinimide 4 by transformation to trans-1-(N,N-dimethylcarboxamido)indane-2-carboxAmide (10c) followed by cyclization of this mixed primary/Tertiary Amide by means of NaH in refluxing THF. Treatment of 20 with KNH2 in liquid NH3 led to intramolecular aryl...

Giovanni F. Caramori - One of the best experts on this subject based on the ideXlab platform.

  • Platinum-triggered Bond-cleavage of Pentynoyl Amide and N-propargyl handles for Drug-Activation
    Journal of the American Chemical Society, 2020
    Co-Authors: Bruno Oliveira, Felipe S. S. Schneider, Benjamin Stenton, João Conde, Magda Negrão, Vb Unnikrishnan, Cátia Rebelo De Almeida, Carlos Cordeiro, Miguel Godinho Ferreira, Giovanni F. Caramori
    Abstract:

    The ability to create ways to control drug activation at specific tissues while sparing healthy tissues remains a major challenge. The administration of exogenous target-specific triggers offers the potential for traceless release of active drugs on tumor sites from antibody−drug conjugates (ADCs) and caged prodrugs. We have developed a metal-mediated bond-cleavage reaction that uses platinum complexes [K 2 PtCl 4 or Cisplatin (CisPt)] for drug activation. Key to the success of the reaction is a water-promoted activation process that triggers the reactivity of the platinum complexes. Under these conditions, the decaging of pentynoyl Tertiary Amides and N-propargyls occurs rapidly in aqueous systems. In cells, the protected analogues of cytotoxic drugs 5fluorouracil (5-FU) and monomethyl auristatin E (MMAE) are partially activated by nontoxic amounts of platinum salts. Additionally, a noninternalizing ADC built with a pentynoyl traceless linker that features a Tertiary Amide protected MMAE was also decaged in the presence of platinum salts for extracellular drug release in cancer cells. Finally, CisPt-mediated prodrug activation of a propargyl derivative of 5-FU was shown in a colorectal zebrafish xenograft model that led to significant reductions in tumor size. Overall, our results reveal a new metal-based cleavable reaction that expands the application of platinum complexes beyond those in catalysis and cancer therapy.